Latest Conference Coverage

Potential of Nasal Foralumab in Treating Non-Active Secondary Progressive MS: Tarun Singhal, MD, MBBS

The associate professor of neurology at Harvard Medical School discussed findings from a study investigating nasal foralumab in patients with non-active secondary progressive multiple sclerosis. [WATCH TIME: 5 minutes]

Understanding the Cognitive Impact of Neighborhood Disadvantage on Black Women: Tanisha Hill-Jarrett, PhD

The neuropsychologist and assistant professor of neurology at the University of California, San Francisco Memory and Aging Center provided comment on her presentation from AAN 2024 examining the association of area deprivation index with cognitive functioning in Black women. [WATCH TIME: 3 minutes]

Use of Antiemetics in Parkinson Care

Optimizing Dosing and Treatment Selection of Amantadine

Insights on Addressing Disparities in Alzheimer Disease Research: Renã A. S. Robinson, PhD

The associate professor of chemistry at Vanderbilt University talked about research surrounding racial and ethnic disparities in Alzheimer disease incidence. [WATCH TIME: 5 minutes]

Therapeutic Potential of Transcranial Direct Current Stimulation in Primary Progressive Aphasia: Leigh Charvet, PhD

The professor of neurology at the NYU Grossman School of Medicine provided commentary on a study that demonstrated the benefits of using tDCS along with sleep language training to promote naming in primary progressive aphasia. [WATCH TIME: 5 minutes]

Examining Promising Phase 2b PARADIGM Findings of ALS Agent PrimeC: Merit Cudkowicz, MD, MSc

The chair of neurology at Massachusetts General Hospital talked about results from the phase 2b PARADIGM trial assessing PrimeC, an ALS combination agent that consists of ciprofloxacin and celecoxib. [WATCH TIME: 4 minutes]

Investigational Agent EDG-5506 Shows Promising 2-Year Data in Becker Muscular Dystrophy

After 2 years of treatment, EDG-5506, otherwise known as sevasemten, was well-tolerated, with rapid and sustained decreases in biomarkers of muscle damage.

Understanding the Clinical Utility of Low-Contrast Letter Acuity and RAN Tasks in Alzheimer Disease

Lauren Seidman, a second-year medical student at NYU Langone’s Grossman School of Medicine, provided perspective on a poster at AAN 2024 highlighting the use of binocular visual function testing in Alzheimer disease.

Safety Considerations for Ravulizumab in NMOSD: Sean Pittock, MD

The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed the safety of ravulizumab and the ways to avoid risks of meningococcal infection. [WATCH TIME: 3 minutes]

Nasal Foralumab Shows Attenuation of Microglial Activation, Clinical Stabilization in Non-Active Secondary Progressive MS With PIRA

Foralumab's anti-CD3 mechanism modulates T cell function, offering potential benefits for the challenging-to-treat na-SPMS patients.

Consistent Efficacy of Eptinezumab as Migraine Prevention Treatment: Jessica Ailani, MD

The director of the MedStar Georgetown Headache Center talked about an intravenous migraine treatment that could offer long-term relief for most patients who respond well to the initial dose. [WATCH TIME: 5 minutes]

Ofatumumab Demonstrates Sustained Efficacy in Recently Diagnosed and Treatment-Naive Relapsing Multiple Sclerosis Over 6 Years

Ofatumumab showed a consistent and long-term reduction in relapse rates and MRI lesion activity in patients with recently diagnosed, treatment-naïve relapsing multiple sclerosis.

Parkinson Gene Therapy AB-1005 Continues to Show Promising Results at 18 Months

Patients experienced improvements in ON/OFF time and motor function, with favorable tolerability, paving the way for a phase 2 trial.

Takotsubo Syndrome and the Brain-Heart Connection: Frederic Schaper, MD, PhD

The instructor in neurology at Brigham and Women's Hospital talked about research exploring takotsubo syndrome, a heart condition often triggered by emotional or physical stressors, and its relationship with brain lesions. [WATCH TIME: 5 minutes]

Advancing MS Care for Minority Populations Using the VISIBL-MS Bilingual Framework: Jaime Imitola, MD

The chief of the Division of MS and Neuroimmunology at UConn Health talked about the unevenly distributed progress in multiple sclerosis care, impacting minority populations who often face worse disease outcomes. [WATCH TIME: 6 minutes]

Impact of Antiepileptic Medications and Sex Hormones on Maternal and Child Outcomes in Epilepsy

Paula Emanuela Voinescu, MD, PhD, director of the Women's Epilepsy Program at Brigham and Women's Hospital, talked about the influence of sex hormones on maternal outcomes in pregnant women with epilepsy treated with antiseizure medication.

A Promising New Approach To Reduce Repeat Surgeries for Subdural Hematomas: Jason M. Davies, MD, PhD

The assistant professor of neurosurgery and biomedical informatics at the State University of New York at Buffalo talked about the potential of embolizing the middle meningeal artery in patients with subdural hematomas. [WATCH TIME: 4 minutes]

Efficacy and Safety of Fremanezumab Consistent in Patients With Migraine and Obesity

Across 2, phase 3 studies, fremanezumab provided significant effects on monthly migraine days, regardless of whether patients were obese or not.

Faster Initiation of Diazepam Nasal Spray Associated With More Rapid Seizure Termination

Even when combining both adult and pediatric patients, diazepam nasal spray administered within 5 minutes of a seizure led to quicker seizure termination.

Integrative and Alternative Patient-Centered Therapies in Neurology: Carolyn Bernstein, MD

The assistant professor of neurology at Harvard Medical School talked about integrative therapies that may offer promising alternatives to traditional treatments for aiding neurological conditions. [WATCH TIME: 5 minutes]

Analysis on the Efficacy of Cenobamate in Pediatric Patients With Refractory Epilepsy

Kate Labiner, MD, a pediatric epileptologist at Child Neurology Consultants of Austin, talked about the potential of cenobamate in pediatric patients with refractory focal epilepsy who have failed multiple medications.

Safety of Cancer Treatments in Patients With Multiple Sclerosis: Prashanth Rajarajan, MD, PhD

The neurology resident at Massachusetts General Brigham talked about assessing the safety of cancer treatments in patients with multiple sclerosis using checkpoint inhibitors. [WATCH TIME: 6 minutes]

Baseline Amyloid PET Centiloid Levels Show No Impact on Lecanemab ARIA-E Rates

Investigators found no trends in amyloid-imaging abnormality rates based on centile tertile levels for lecanemab-treated patients.

ALZ-801 Shows Reduction in Relevant Alzheimer Biomarkers, Clearance of Amyloid After 2 Years

Patients treated with ALZ-801 showed improvements in cognition, reduced brain atrophy, and maintained dementia rating stages.

Researching Cannabis Use Disorder in Multiple Sclerosis: Leigh Charvet, PhD

The professor of neurology at the NYU Grossman School of Medicine discussed a study presented at AAN 2024 highlighting the risks of cannabis use in patients with multiple sclerosis. [WATCH TIME: 4 minutes]

Analysis of Low-sodium Oxybate Proposes Minimal Clinically Important Difference in Visual Analog Scale for Sleep Inertia

An analysis of a phase 3 trial of low sodium oxybate in patients with idiopathic hypersomnia identified a minimal clinically important difference in the visual analog scale for sleep inertia.

Pregnancy Outcomes of Maternal Exposure to Ocrelizumab: Riley Bove, MD

The associate professor of neurology at University of California, San Francisco talked about findings from an analysis that assessed the safety of ocrelizumab when administered close to pregnancy. [WATCH TIME: 5 minutes]

Switching to Subcutaneous Zilucoplan Raises No Safety Concerns in Myasthenia Gravis

A phase 3b study showed that switching from intravenous C5 inhibitors to subcutaneous zilucoplan in patients with myasthenia gravis was associated with symptom improvement at 12 weeks.

Improvements in Alzheimer Agitation, Response Rates Seen Through Brexpiprazole

Over 2, phase 3 studies, brexpiprazole-treated patients demonstrated greater response rates across various levels on the Cohen-Mansfield Agitation Index and Clinical Impression Scale-Improvement assessment.